Madrigal raises $500M for NASH drug launch, discloses cyberattack
Madrigal Pharmaceuticals expects to raise $500 million from a stock and warrants sale, which it plans to use to prepare for the launch of resmetirom …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
